Adagio Closes $42.5M Financing To Develop Ablation Technologies
The series E financing will support the ongoing US trial of Adagio’s iCLAS cardiac cryoablation system and development of Adagio's pulsed field cryoablation technology while the company continues to commercialize iCLAS outside the US.
You may also be interested in...
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.